Lipid management in Type 2 diabetes: the case for combination therapy?

Authors: Saely, Christoph H; Drexel, Veronika; Vonbank, Alexander; Drexel, Heinz

Source: Therapy, 1 March 2011, vol. 8, no. 2, pp. 129-141(13)


Buy & download fulltext article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.


Cardiovascular disease determines the prognosis of patients with Type 2 diabetes, and because lipids play a central role in atherogenesis, lipid management in diabetic patients is of paramount importance. Given the large body of evidence demonstrating the cardiovascular risk reduction with the primarily low-density lipoprotein-lowering statins, these drugs represent the basis of lipid management in patients with Type 2 diabetes. However, the majority of cardiovascular events even with potent statin therapy cannot be prevented. Combination therapy with other lipid-lowering interventions therefore appears interesting as it may provide additional benefit. Data on the safety and efficacy of combination lipid therapy from large outcome trials are still limited. However, the evidence already available provides a rationale for combination lipid therapy in patients with Type 2 diabetes.

Keywords: Type 2 diabetes; anion exchange resins; ezetimibe; fibrates; lipid therapy; niacin; omega-3 fatty acids; pioglitazone; statins

Document Type: Research Article


Publication date: March 1, 2011

Related content


Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page